List of Excipients in API phentermine and topiramate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing phentermine and topiramate
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Vivus Inc | QSYMIA | phentermine and topiramate | 62541-201 | CELLULOSE, MICROCRYSTALLINE | |
| Vivus Inc | QSYMIA | phentermine and topiramate | 62541-201 | ETHYLCELLULOSE | |
| Vivus Inc | QSYMIA | phentermine and topiramate | 62541-201 | FD&C BLUE NO. 1 | |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for phentermine and topiramate
Excipient focus: CELLULOSE, MICROCRYSTALLINE
phentermine and topiramate drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ETHYLCELLULOSE
phentermine and topiramate drug variants containing ETHYLCELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing ETHYLCELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
phentermine and topiramate drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C RED NO. 3
phentermine and topiramate drug variants containing FD&C RED NO. 3
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing FD&C RED NO. 3
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 5
phentermine and topiramate drug variants containing FD&C YELLOW NO. 5
| Company | Ingredient | NDC |
|---|---|---|
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing FD&C YELLOW NO. 5
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
phentermine and topiramate drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| >Company | >Ingredient | >NDC |
Excipient focus: GELATIN
phentermine and topiramate drug variants containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing GELATIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
phentermine and topiramate drug variants containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: STARCH, CORN
phentermine and topiramate drug variants containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing STARCH, CORN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
phentermine and topiramate drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
phentermine and topiramate drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
phentermine and topiramate drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Vivus Inc | phentermine and topiramate | 62541-201 |
| Vivus LLC | phentermine and topiramate | 62541-202 |
| >Company | >Ingredient | >NDC |
phentermine and topiramate drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
